Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Biofrontera Inc. Warrants (BFRIW)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/26/2025: BFRIW (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $0
1 Year Target Price $0
| 0 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -53.12% | Avg. Invested days 30 | Today’s Advisory WEAK BUY |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 06/26/2025 |
Key Highlights
Company Size ETF | Market Capitalization 0 USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta 0.3 | 52 Weeks Range 0.01 - 0.23 | Updated Date 06/3/2025 |
52 Weeks Range 0.01 - 0.23 | Updated Date 06/3/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.3 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -30.33% | Operating Margin (TTM) -52.95% |
Management Effectiveness
Return on Assets (TTM) -49.47% | Return on Equity (TTM) -384.98% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value - | Price to Sales(TTM) - |
Enterprise Value - | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding - | Shares Floating 7102407 |
Shares Outstanding - | Shares Floating 7102407 | ||
Percent Insiders - | Percent Institutions - |
Analyst Ratings
Rating - | Target Price - | Buy - | Strong Buy - |
Buy - | Strong Buy - | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Biofrontera Inc. Warrants
Company Overview
History and Background
Biofrontera Inc. is a biopharmaceutical company specializing in the development and commercialization of pharmaceutical products for the treatment of skin diseases. The warrants are securities that give the holder the right to purchase Biofrontera AG (BFRA) shares at a specified price within a specific period. Warrants are often issued as part of a financing deal.
Core Business Areas
- Pharmaceutical Products: Development and commercialization of pharmaceuticals for dermatological conditions.
- Warrant Offering: Issuance of warrants as part of corporate financing strategies, offering potential future equity participation.
Leadership and Structure
Biofrontera AG has a management board and a supervisory board. The warrant terms are governed by the warrant agreement.
Top Products and Market Share
Key Offerings
- Ameluz: A prescription drug approved for the treatment of actinic keratoses. Global sales are estimated to be in the millions. Competitors include photodynamic therapy devices and other topical treatments. Market share for Ameluz within the photodynamic therapy market is significant, but exact figures are difficult to ascertain.
- BF-RhodoLED: Medical Device used with Ameluz for Photodynamic Therapy (PDT). Revenue generated is linked to the sale of Ameluz. Competitors include other PDT light sources.
Market Dynamics
Industry Overview
The biopharmaceutical industry is competitive, with constant innovation in dermatological treatments. Market growth is driven by aging populations and increased awareness of skin conditions.
Positioning
Biofrontera focuses on photodynamic therapy for skin cancer prevention. Its competitive advantage lies in the clinical efficacy of its Ameluz product.
Total Addressable Market (TAM)
The global dermatology market is substantial. Biofrontera's focus on actinic keratosis places it within a segment with a large TAM. Specific TAM figures for their niche are readily available via industry reports.
Upturn SWOT Analysis
Strengths
- FDA-approved product (Ameluz)
- Established distribution network
- Strong clinical data supporting efficacy
- Proprietary PDT technology
Weaknesses
- Reliance on a single key product
- Competition from larger pharmaceutical companies
- Potential regulatory hurdles
- Warrant dilution
Opportunities
- Expanding indications for Ameluz
- Entering new geographic markets
- Developing new dermatological products
- Strategic partnerships
Threats
- Patent expiration
- Generic competition
- Changes in reimbursement policies
- Unfavorable clinical trial results
Competitors and Market Share
Key Competitors
- LEO Pharma (private)
- Galderma (private)
- Sun Pharmaceutical (SUNPHARMA.NS)
Competitive Landscape
Biofrontera's competitive advantage lies in its specific PDT technology, but larger companies have broader portfolios and greater resources.
Growth Trajectory and Initiatives
Historical Growth: Historical growth should focus on Ameluz sales growth and market penetration of Biofrontera AG (BFRA).
Future Projections: Future projections should consider analyst estimates for Biofrontera AG (BFRA) revenue and profitability. Warrants will depend on the price movement on Biofrontera AG (BFRA).
Recent Initiatives: Recent initiatives should include new clinical trials, product launches, and partnerships of Biofrontera AG (BFRA).
Summary
Biofrontera warrants provide an opportunity to participate in the potential growth of Biofrontera AG. The warrant value is highly dependent on the performance of Ameluz and overall Biofrontera AG financial health. However, the company faces intense competition and regulatory hurdles. Investors should carefully consider the risks associated with warrants, including potential dilution. The success of Ameluz is the main driver of future growth.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company filings
- Analyst reports
- Industry publications
Disclaimers:
This analysis is for informational purposes only and should not be considered financial advice. Investing in warrants involves significant risk. Please consult with a qualified financial advisor before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Biofrontera Inc. Warrants
Exchange NASDAQ | Headquaters Woburn, MA, United States | ||
IPO Launch date 2021-10-29 | CEO, President & Chairman Dr. Hermann Luebbert Ph.D. | ||
Sector Healthcare | Industry Drug Manufacturers - Specialty & Generic | Full time employees 92 | Website https://www.biofrontera-us.com |
Full time employees 92 | Website https://www.biofrontera-us.com | ||
Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a common skin infection. It offers Ameluz, a prescription drug for use in combination with the RhodoLED lamp series, for photodynamic therapy for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp. The company also provides Xepi, a topical non-fluorinated quinolone that inhibits bacterial growth for the treatment of impetigo. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.